Literature DB >> 17461758

Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.

Juliana M Layzer1, Bruce A Sullenger.   

Abstract

By using the in vitro selection method SELEX against the complex mixture of GLA proteins and utilizing methods to deconvolute the resulting ligands, we were able to successfully generate 2'-ribo purine, 2'-fluoro pyrimidine aptamers to various individual targets in the GLA protein proteome that ranged in concentration from 10 nM to 1.4 microM in plasma. Perhaps not unexpectedly, the majority of the aptamers isolated following SELEX bind the most abundant protein in the mixture, prothrombin (FII), with high affinity. We show that by deselecting the dominant prothrombin aptamer the selection can be redirected. By using this DeSELEX approach, we were able to shift the selection toward other sequences and to less abundant protein targets and obtained an aptamer to Factor IX (FIX). We also demonstrate that by using an RNA library that is focused around a proteome, purified protein targets can then be used to rapidly generate aptamers to the protein targets that are rare in the initial mixture such as Factor VII (FVII) and Factor X (FX). Moreover, for all four proteins targeted (FII, FVII, FIX, and FX), aptamers were identified that could inhibit the individual protein's activitity in coagulation assays. Thus, by applying the concepts of DeSELEX and focused library selection, aptamers specific for any protein in a particular proteome can theoretically be generated, even when the proteins in the mixture are present at very different concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461758     DOI: 10.1089/oli.2006.0059

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  31 in total

1.  Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

Authors:  Erin E Soule; Kristin M Bompiani; Rebecca S Woodruff; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2015-11-19       Impact factor: 5.486

2.  2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.

Authors:  Youngju Lee; Johannes H Urban; Li Xu; Bruce A Sullenger; Jaewoo Lee
Journal:  Nucleic Acid Ther       Date:  2016-01-20       Impact factor: 5.486

3.  Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery.

Authors:  Jan Hoinka; Alexey Berezhnoy; Phuong Dao; Zuben E Sauna; Eli Gilboa; Teresa M Przytycka
Journal:  Nucleic Acids Res       Date:  2015-04-13       Impact factor: 16.971

Review 4.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

5.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

6.  Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

Authors:  Kristin M Bompiani; Jens L Lohrmann; George A Pitoc; James W Frederiksen; George B Mackensen; Bruce A Sullenger
Journal:  Chem Biol       Date:  2014-07-24

7.  A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.

Authors:  K M Bompiani; D M Monroe; F C Church; B A Sullenger
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

Review 8.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

9.  Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing.

Authors:  Alexey Berezhnoy; C Andrew Stewart; James O Mcnamara; William Thiel; Paloma Giangrande; Giorgio Trinchieri; Eli Gilboa
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

10.  Therapeutic Aptamers: Evolving to Find their Clinical Niche.

Authors:  Shahid M Nimjee; Bruce A Sullenger
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.